Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts

Executive Summary

FDA 'strongly encouraged' Sandoz to conduct three-way clinical PK/PD study comparing its Zarxio biosimilar to the EU- and U.S.-approved versions of Amgen’s Neupogen; however, the firm succeeded in using only analytical data to justify relevance of studies using the European reference product.


Related Content

Will Fortune Favor The Brave? Biosimilar Sponsors Need High Tolerance For Uncertainty
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability
How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz
Sorry, Wrong Email: FDA’s ‘Oops’ Moment In The Zarxio Review
Zarxio Reviewers
FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared
Zarxio Clinical Development Timeline
Biosimilar Guidances: Broader Populations Permitted; More Immunogenicity Requested
FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics
Biosimilar User Fee Agreement Allows For Reliance On Foreign Clinical Data, FDAer Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts